ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW
Alvotech
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$5.03+0.03 (+0.60%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 50.3
- Dividend yield
- –
Alvotech revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Europe | $307.22M | $157.59M | $63.51M | $39.43M | $20.51M | $19.71M | 52.4% | +95.0% |
| United States | $241.37M | $273.04M | $9.43M | $17.94M | – | – | 41.2% | -11.6% |
| Rest of World | $37.73M | $59.06M | $18.49M | $25.66M | – | – | 6.4% | -36.1% |
| North America | – | – | $18.31M | $30.78M | $11.66M | $37.93M | – | – |
| Other Geographical Area [Member] | – | – | – | $6.02M | $3.28M | $4.87M | – | – |
| Asia [Member] | – | – | – | $6.80M | $1.32M | $4.11M | – | – |
| Asia and Other | – | – | $9.62M | $12.82M | $4.60M | – | – | – |
From the segment and revenue-disaggregation notes of Alvotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.